{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:47:33Z","timestamp":1782089253702,"version":"3.54.5"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01337-4","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:44:05Z","timestamp":1776746645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized metabolite biomarker predictions reveal heterogeneous characteristics of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Ecehan","family":"Abdik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunahan","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1337_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"1337_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"1337_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1326-4-24","volume":"4","author":"KA Malkus","year":"2009","unstructured":"Malkus, K. A., Tsika, E. & Ischiropoulos, H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson\u2019s disease: how neurons are lost in the Bermuda triangle. Mol. Neurodegener. 4, 24 (2009).","journal-title":"Mol. Neurodegener."},{"key":"1337_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1039\/D2MO00343K","volume":"19","author":"R Odongo","year":"2023","unstructured":"Odongo, R., Bellur, O., Abdik, E. & \u00c7ak\\ir, T. Brain-wide transcriptome-based metabolic alterations in Parkinson\u2019s disease: human inter-region and human-experimental model correlations. Mol. Omics. 19, 522\u2013537 (2023).","journal-title":"Mol. Omics."},{"key":"1337_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/mds.26510","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson\u2019s disease subtypes. Mov. Disord. 31, 1095\u20131102 (2016).","journal-title":"Mov. Disord."},{"key":"1337_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","volume":"76","author":"E De Pablo-Fern\u00e1ndez","year":"2019","unstructured":"De Pablo-Fern\u00e1ndez, E., Lees, A. J., Holton, J. L. & Warner, T. T. Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol. 76, 470\u2013479 (2019).","journal-title":"JAMA Neurol."},{"key":"1337_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41531-022-00439-z","volume":"8","author":"A Dadu","year":"2022","unstructured":"Dadu, A. et al. Identification and prediction of Parkinson\u2019s disease subtypes and progression using machine learning in two cohorts. npj Park. Dis. 8, 172 (2022).","journal-title":"npj Park. Dis."},{"key":"1337_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1337_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter, D. T. & Jenner, P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62, 132\u2013144 (2013).","journal-title":"Free Radic. Biol. Med."},{"key":"1337_CR10","doi-asserted-by":"publisher","first-page":"117957352412868","DOI":"10.1177\/11795735241286821","volume":"17","author":"C Fabrizio","year":"2025","unstructured":"Fabrizio, C., Termine, A. & Caltagirone, C. Transcriptomics profiling of Parkinson\u2019s disease progression subtypes reveals distinctive patterns of gene expression. J. Cent. Nerv. Syst. Dis. 17, 11795735241286820 (2025).","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"1337_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00401-023-02597-7","volume":"146","author":"C Cappelletti","year":"2023","unstructured":"Cappelletti, C. et al. Transcriptomic profiling of Parkinson\u2019s disease brains reveals disease stage specific gene expression changes. Acta Neuropathol. 146, 227\u2013244 (2023).","journal-title":"Acta Neuropathol."},{"key":"1337_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajmg.b.30195","volume":"137","author":"Y Zhang","year":"2005","unstructured":"Zhang, Y., James, M., Middleton, F. A. & Davis, R. L. Transcriptional analysis of multiple brain regions in Parkinson\u2019s disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 137, 5\u201316 (2005).","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"1337_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/1535370220967325","volume":"246","author":"L Kurvits","year":"2021","unstructured":"Kurvits, L. et al. Transcriptomic profiles in Parkinson\u2019s disease. Exp. Biol. Med. 246, 584\u2013595 (2021).","journal-title":"Exp. Biol. Med."},{"key":"1337_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2018.07.002","volume":"33","author":"L Fuhr","year":"2018","unstructured":"Fuhr, L. et al. The circadian clock regulates metabolic phenotype rewiring via HKDC1 and modulates tumor progression and drug response in colorectal cancer. EBioMedicine 33, 105\u2013121 (2018).","journal-title":"EBioMedicine"},{"key":"1337_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.15252\/msb.20145307","volume":"11","author":"K Yizhak","year":"2015","unstructured":"Yizhak, K., Chaneton, B., Gottlieb, E. & Ruppin, E. Modeling cancer metabolism on a genome scale. Mol. Syst. Biol. 11, 817 (2015).","journal-title":"Mol. Syst. Biol."},{"key":"1337_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41514-021-00064-9","volume":"7","author":"VR Varma","year":"2021","unstructured":"Varma, V. R. et al. Abnormal brain cholesterol homeostasis in Alzheimer\u2019s disease\u2014a targeted metabolomic and transcriptomic study. npj Aging Mech. Dis. 7, 1\u201314 (2021).","journal-title":"npj Aging Mech. Dis."},{"key":"1337_CR17","doi-asserted-by":"crossref","unstructured":"\u00c7akir, T., Abdik, E., Uzuner, D. & L\u00fcleci, H. B. Genome-scale metabolic modeling for disease. In Encyclopedia of Bioinformatics and Computational Biology 2nd edn (eds Ranganathan, S., Cannataro, M. & Khan, A. M.) 258\u2013265 (Elsevier, 2025).","DOI":"10.1016\/B978-0-323-95502-7.00227-X"},{"key":"1337_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/biomedicines9101310","volume":"9","author":"S Lam","year":"2021","unstructured":"Lam, S. et al. Systems analysis reveals ageing-related perturbations in retinoids and sex hormones in Alzheimer\u2019s and Parkinson\u2019s diseases. Biomedicines 9, 1310 (2021).","journal-title":"Biomedicines"},{"key":"1337_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s42003-023-05548-w","volume":"6","author":"A Zagare","year":"2023","unstructured":"Zagare, A. et al. Omics data integration suggests a potential idiopathic Parkinson\u2019s disease signature. Commun. Biol. 6, 1179 (2023).","journal-title":"Commun. Biol."},{"key":"1337_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14250","volume":"8","author":"EM Blais","year":"2017","unstructured":"Blais, E. M. et al. Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions. Nat. Commun. 8, 14250 (2017).","journal-title":"Nat. Commun."},{"key":"1337_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/toxsci\/kfz228","volume":"173","author":"VR Pannala","year":"2020","unstructured":"Pannala, V. R. et al. Genome-scale model-based identification of metabolite indicators for early detection of kidney toxicity. Toxicol. Sci. 173, 293\u2013312 (2020).","journal-title":"Toxicol. Sci."},{"key":"1337_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/toxsci\/kfz197","volume":"172","author":"KD Rawls","year":"2019","unstructured":"Rawls, K. D. et al. Genome-Scale Characterization of Toxicity-Induced Metabolic Alterations in Primary Hepatocytes. Toxicol. Sci. 172, 279\u2013291 (2019).","journal-title":"Toxicol. Sci."},{"key":"1337_CR23","doi-asserted-by":"crossref","unstructured":"Abdik, E. & Cakir, T. Systematic investigation of mouse models of Parkinson\u2019s disease by transcriptome mapping on a brain-specific genome-scale metabolic network. Mol. Omics. 17.4, 492\u2212502 (2021).","DOI":"10.1039\/D0MO00135J"},{"key":"1337_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-51034-y","volume":"14","author":"E Abdik","year":"2024","unstructured":"Abdik, E. & Cakir, T. Transcriptome-based biomarker prediction for Parkinson\u2019s disease using genome-scale metabolic modeling. Sci. Rep. 14, 585 (2024).","journal-title":"Sci. Rep."},{"key":"1337_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res"},{"key":"1337_CR26","doi-asserted-by":"crossref","unstructured":"Robinson, J. L. et al. An atlas of human metabolism. Sci. Signal. 13, eaaz1482 (2020).","DOI":"10.1126\/scisignal.aaz1482"},{"key":"1337_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49268-z","volume":"15","author":"M de los Santos","year":"2024","unstructured":"de los Santos, M. et al. Divergent landscapes of A-to-I editing in postmortem and living human brain. Nat. Commun. 15, 5366 (2024).","journal-title":"Nat. Commun."},{"key":"1337_CR28","doi-asserted-by":"publisher","first-page":"784314","DOI":"10.3389\/fnagi.2022.784314","volume":"14","author":"H Ma","year":"2022","unstructured":"Ma, H., Yan, J., Sun, W., Jiang, M. & Zhang, Y. Melatonin treatment for sleep disorders in Parkinson\u2019s disease: a meta-analysis and systematic review. Front. Aging Neurosci. 14, 784314 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1337_CR29","first-page":"3789","volume":"55","author":"X Cao","year":"2018","unstructured":"Cao, X., Cao, L., Ding, L. & Bian, J. A new hope for a devastating disease: hydrogen sulfide in Parkinson\u2019s disease. Mol. Neurobiol. 55, 3789\u20133799 (2018).","journal-title":"Mol. Neurobiol."},{"key":"1337_CR30","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/mds.21048","volume":"21","author":"JA demarcaida","year":"2006","unstructured":"demarcaida, J. A. et al. Effects of tyramine administration in Parkinson\u2019s disease patients treated with selective MAO-B inhibitor rasagiline. Mov. Disord. 21, 1716\u20131721 (2006).","journal-title":"Mov. Disord."},{"key":"1337_CR31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1046\/j.1471-4159.2002.00871.x","volume":"81","author":"JO Rinne","year":"2002","unstructured":"Rinne, J. O. et al. Increased brain histamine levels in Parkinson\u2019s disease but not in multiple system atrophy. J. Neurochem. 81, 954\u2013960 (2002).","journal-title":"J. Neurochem."},{"key":"1337_CR32","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res"},{"key":"1337_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"J Meiser","year":"2013","unstructured":"Meiser, J., Weindl, D. & Hiller, K. Complexity of dopamine metabolism. Cell Commun. Signal. 11, 34 (2013).","journal-title":"Cell Commun. Signal."},{"key":"1337_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2174\/1871527319666200902134129","volume":"19","author":"SM Voon","year":"2020","unstructured":"Voon, S. M. et al. The mechanism of action of salsolinol in brain: implications in Parkinson\u2019s disease. CNS Neurol. Disord. Targets (Former. Curr. Drug Targets-CNS Neurol. Disord. 19, 725\u2013740 (2020).","journal-title":"Disord. Targets (Former. Curr. Drug Targets-CNS Neurol. Disord."},{"key":"1337_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0006-3223(96)00408-8","volume":"42","author":"L Antkiewicz-Michaluk","year":"1997","unstructured":"Antkiewicz-Michaluk, L., Krygowska-Wajs, A., Szczudlik, A., Roma\u0144ska, I. & Vetulani, J. Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biol. Psychiatry 42, 514\u2013518 (1997).","journal-title":"Biol. Psychiatry"},{"key":"1337_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF01276418","volume":"103","author":"A Moser","year":"1996","unstructured":"Moser, A., Siebecker, F., Vieregge, P., Jaskowski, P. & K\u00f6mpf, D. Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson\u2019s disease. J. Neural Transm. 103, 421\u2013432 (1996).","journal-title":"J. Neural Transm."},{"key":"1337_CR37","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1337_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.neuropharm.2012.11.010","volume":"67","author":"BJ Stansley","year":"2013","unstructured":"Stansley, B. J. & Yamamoto, B. K. L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology 67, 243\u2013251 (2013).","journal-title":"Neuropharmacology"},{"key":"1337_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1389202914666131210213042","volume":"15","author":"J Dorszewska","year":"2014","unstructured":"Dorszewska, J., Prendecki, M., Lianeri, M. & Kozubski, W. Molecular effects of L-dopa therapy in Parkinson\u2019s disease. Curr. Genomics 15, 11\u201317 (2014).","journal-title":"Curr. Genomics"},{"key":"1337_CR40","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.fshw.2022.10.011","volume":"12","author":"S Park","year":"2023","unstructured":"Park, S. et al. 4-Hydroxycinnamic acid attenuates neuronal cell death by inducing expression of plasma membrane redox enzymes and improving mitochondrial functions. Food Sci. Hum. Wellness 12, 1287\u20131299 (2023).","journal-title":"Food Sci. Hum. Wellness"},{"key":"1337_CR41","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3390\/biomedicines10092255","volume":"10","author":"M Medvedeva","year":"2022","unstructured":"Medvedeva, M. et al. Hydroxycinnamic acid derivatives from coffee extracts prevent amyloid transformation of alpha-synuclein. Biomedicines 10, 2255 (2022).","journal-title":"Biomedicines"},{"key":"1337_CR42","doi-asserted-by":"publisher","first-page":"e0191670","DOI":"10.1371\/journal.pone.0191670","volume":"13","author":"M Figura","year":"2018","unstructured":"Figura, M. et al. Serum amino acid profile in patients with Parkinson\u2019s disease. PLoS One 13, e0191670 (2018).","journal-title":"PLoS One"},{"key":"1337_CR43","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ene.14470","volume":"27","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2020","unstructured":"Jim\u00e9nez-Jim\u00e9nez, F. J., Alonso-Navarro, H., Garc\u00eda-Mart\u00edn, E. & Ag\u00fandez, J. A. G. Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson\u2019s disease: review and meta-analysis. Eur. J. Neurol. 27, 2336\u20132347 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1337_CR44","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.3390\/biomedicines10123005","volume":"10","author":"P G\u0105tarek","year":"2022","unstructured":"G\u0105tarek, P. et al. Plasma metabolic disturbances in Parkinson\u2019s disease patients. Biomedicines 10, 3005 (2022).","journal-title":"Biomedicines"},{"key":"1337_CR45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/antiox11050848","volume":"11","author":"C Solana-Manrique","year":"2022","unstructured":"Solana-Manrique, C., Sanz, F. J., Mart\u00ednez-Carri\u00f3n, G. & Paricio, N. Antioxidant and neuroprotective effects of carnosine: therapeutic implications in neurodegenerative diseases. Antioxidants 11, 848 (2022).","journal-title":"Antioxidants"},{"key":"1337_CR46","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3892\/etm.2017.4571","volume":"14","author":"J Zhao","year":"2017","unstructured":"Zhao, J., Shi, L. & Zhang, L.-R. Neuroprotective effect of carnosine against salsolinol-induced Parkinson\u2019s disease. Exp. Ther. Med. 14, 664\u2013670 (2017).","journal-title":"Exp. Ther. Med."},{"key":"1337_CR47","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/cells13221876","volume":"13","author":"A Tanvir","year":"2024","unstructured":"Tanvir, A., Jo, J. & Park, S. M. Targeting glucose metabolism: a novel therapeutic approach for Parkinson\u2019s disease. Cells 13, 1876 (2024).","journal-title":"Cells"},{"key":"1337_CR48","doi-asserted-by":"publisher","first-page":"110672","DOI":"10.1016\/j.brainresbull.2023.110672","volume":"199","author":"C Dai","year":"2023","unstructured":"Dai, C. et al. Glucose metabolism impairment in Parkinson\u2019s disease. Brain Res. Bull. 199, 110672 (2023).","journal-title":"Brain Res. Bull."},{"key":"1337_CR49","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/mds.27132","volume":"32","author":"J-P Trezzi","year":"2017","unstructured":"Trezzi, J.-P. et al. Distinct metabolomic signature in cerebrospinal fluid in early parkinson\u2019s disease. Mov. Disord. 32, 1401\u20131408 (2017).","journal-title":"Mov. Disord."},{"key":"1337_CR50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neulet.2015.03.051","volume":"594","author":"A \u00d6hman","year":"2015","unstructured":"\u00d6hman, A. & Forsgren, L. NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson\u2019s disease and controls. Neurosci. Lett. 594, 36\u201339 (2015).","journal-title":"Neurosci. Lett."},{"key":"1337_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1423-0127-16-63","volume":"16","author":"SSSJ Ahmed","year":"2009","unstructured":"Ahmed, S. S. S. J., Santosh, W., Kumar, S. & Christlet, H. T. T. Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 16, 1\u201312 (2009).","journal-title":"J. Biomed. Sci."},{"key":"1337_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02260943","volume":"8","author":"C Mytilineou","year":"1994","unstructured":"Mytilineou, C. et al. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson\u2019s disease. J. neural Transm. Dis. Dement. Sect. 8, 223\u2013228 (1994).","journal-title":"J. neural Transm. Dis. Dement. Sect."},{"key":"1337_CR53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1039\/C5MB00711A","volume":"12","author":"A Wuolikainen","year":"2016","unstructured":"Wuolikainen, A. et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson\u2019s disease and control subjects. Mol. Biosyst. 12, 1287\u20131298 (2016).","journal-title":"Mol. Biosyst."},{"key":"1337_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells8010027","volume":"8","author":"H Xicoy","year":"2019","unstructured":"Xicoy, H., Wieringa, B. & Martens, G. J. M. The role of lipids in Parkinson\u2019s disease. Cells 8, 27 (2019).","journal-title":"Cells"},{"key":"1337_CR55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/biom12030346","volume":"12","author":"K Strempfl","year":"2022","unstructured":"Strempfl, K. et al. Leukotriene signaling as a target in $\u03b1$-synucleinopathies. Biomolecules 12, 346 (2022).","journal-title":"Biomolecules"},{"key":"1337_CR56","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuropharm.2013.06.014","volume":"73","author":"K-H Kang","year":"2013","unstructured":"Kang, K.-H., Liou, H.-H., Hour, M.-J., Liou, H.-C. & Fu, W.-M. Protection of dopaminergic neurons by 5-lipoxygenase inhibitor. Neuropharmacology 73, 380\u2013387 (2013).","journal-title":"Neuropharmacology"},{"key":"1337_CR57","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13311-020-00836-3","volume":"17","author":"J Marschallinger","year":"2020","unstructured":"Marschallinger, J. et al. The leukotriene receptor antagonist montelukast reduces alpha-synuclein load and restores memory in an animal model of dementia with lewy bodies. Neurotherapeutics 17, 1061\u20131074 (2020).","journal-title":"Neurotherapeutics"},{"key":"1337_CR58","doi-asserted-by":"publisher","first-page":"946813","DOI":"10.1155\/2012\/946813","volume":"2012","author":"IV Lima","year":"2012","unstructured":"Lima, I. V. et al. Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Med. Inflamm. 2012, 946813 (2012).","journal-title":"Med. Inflamm."},{"key":"1337_CR59","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1007\/s12035-015-9355-3","volume":"53","author":"T Yagami","year":"2016","unstructured":"Yagami, T., Koma, H. & Yamamoto, Y. Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol. Neurobiol. 53, 4754\u20134771 (2016).","journal-title":"Mol. Neurobiol."},{"key":"1337_CR60","doi-asserted-by":"publisher","first-page":"e17299","DOI":"10.1371\/journal.pone.0017299","volume":"6","author":"D Cheng","year":"2011","unstructured":"Cheng, D. et al. Lipid pathway alterations in Parkinson\u2019s disease primary visual cortex. PLoS One 6, e17299 (2011).","journal-title":"PLoS One"},{"key":"1337_CR61","doi-asserted-by":"crossref","unstructured":"Singh, P. et al. Sulfamerazine as a potential modulator against $\u03b1$-synuclein aggregation and associated toxicity. ACS Chem. Neurosci. 16, 880\u2013894 (2025).","DOI":"10.1021\/acschemneuro.4c00803"},{"key":"1337_CR62","doi-asserted-by":"publisher","first-page":"105112","DOI":"10.1016\/j.chemphyslip.2021.105112","volume":"239","author":"M-X Dong","year":"2021","unstructured":"Dong, M.-X., Wei, Y.-D. & Hu, L. The disturbance of lipid metabolism is correlated with neuropsychiatric symptoms in patients with Parkinson\u2019s disease. Chem. Phys. Lipids 239, 105112 (2021).","journal-title":"Chem. Phys. Lipids"},{"key":"1337_CR63","doi-asserted-by":"publisher","first-page":"621508","DOI":"10.3389\/fnagi.2021.621508","volume":"13","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. Increased plasma heme oxygenase-1 levels in patients with early-stage Parkinson\u2019s disease. Front. Aging Neurosci. 13, 621508 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"1337_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4062\/biomolther.2024.224","volume":"33","author":"NB Campomayor","year":"2025","unstructured":"Campomayor, N. B., Kim, H. J. & Kim, M. Pro-oxidative and inflammatory actions of extracellular hemoglobin and heme: Molecular events and implications for Alzheimer\u2019s and Parkinson disease. Biomol. Ther. (Seoul.). 33, 235 (2025).","journal-title":"Biomol. Ther. (Seoul.)."},{"key":"1337_CR65","first-page":"1","volume":"2","author":"J Freed","year":"2016","unstructured":"Freed, J. & Chakrabarti, L. Defining a role for hemoglobin in Parkinson\u2019s disease. npj Park. Dis. 2, 1\u20134 (2016).","journal-title":"npj Park. Dis."},{"key":"1337_CR66","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","volume":"20","author":"N Ostrerova-Golts","year":"2000","unstructured":"Ostrerova-Golts, N. et al. The A53T $\u03b1$-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048\u20136054 (2000).","journal-title":"J. Neurosci."},{"key":"1337_CR67","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/cells13221874","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Dysregulated coagulation in Parkinson\u2019s Disease. Cells 13, 1874 (2024).","journal-title":"Cells"},{"key":"1337_CR68","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0304-3940(01)01748-7","volume":"303","author":"DJ Sanchez","year":"2001","unstructured":"Sanchez, D. J. et al. Haptoglobin gene expression in human glioblastoma cell lines. Neurosci. Lett. 303, 181\u2013184 (2001).","journal-title":"Neurosci. Lett."},{"key":"1337_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/01.jnen.0000196133.74087.cb","volume":"65","author":"T Arai","year":"2006","unstructured":"Arai, T., Miklossy, J., Klegeris, A., Guo, J.-P. & McGeer, P. L. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 65, 19\u201325 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1337_CR70","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/j.1471-4159.2007.04976.x","volume":"103","author":"T Moos","year":"2007","unstructured":"Moos, T., Nielsen, T. R., Skj\u00f8rringe, T. & Morgan, E. H. Iron trafficking inside the brain. J. Neurochem. 103, 1730\u20131740 (2007).","journal-title":"J. Neurochem."},{"key":"1337_CR71","doi-asserted-by":"publisher","first-page":"e0116641","DOI":"10.1371\/journal.pone.0116641","volume":"10","author":"S Lehri-Boufala","year":"2015","unstructured":"Lehri-Boufala, S. et al. New roles of glycosaminoglycans in $\u03b1$-synuclein aggregation in a cellular model of Parkinson disease. PLoS One 10, e0116641 (2015).","journal-title":"PLoS One"},{"key":"1337_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69480-3","volume":"10","author":"R Raghunathan","year":"2020","unstructured":"Raghunathan, R., Hogan, J. D., Labadorf, A., Myers, R. H. & Zaia, J. A glycomics and proteomics study of aging and Parkinson\u2019s disease in human brain. Sci. Rep. 10, 12804 (2020).","journal-title":"Sci. Rep."},{"key":"1337_CR73","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1002\/1873-3468.13082","volume":"592","author":"A Ma\u00efza","year":"2018","unstructured":"Ma\u00efza, A. et al. The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Lett. 592, 3806\u20133818 (2018).","journal-title":"FEBS Lett."},{"key":"1337_CR74","doi-asserted-by":"crossref","unstructured":"Yan, S. et al. Neurotransmitter imbalance, glutathione depletion and concomitant susceptibility increase in Parkinson\u2019s disease. NeuroImage Clin. 45, 103740 (2025).","DOI":"10.1016\/j.nicl.2025.103740"},{"key":"1337_CR75","doi-asserted-by":"crossref","unstructured":"Dong, H. et al. High selectivity fluorescence and electrochemical dual-mode detection of glutathione in the serum of Parkinson\u2019s disease model mice and humans. Anal. Chem. 97, 1318\u20131328 (2025).","DOI":"10.1021\/acs.analchem.4c05627"},{"key":"1337_CR76","doi-asserted-by":"publisher","first-page":"9409363","DOI":"10.1155\/2016\/9409363","volume":"2016","author":"LK Mischley","year":"2016","unstructured":"Mischley, L. K. et al. Glutathione as a biomarker in Parkinson\u2019s disease: Associations with aging and disease severity. Oxid. Med. Cell. Longev. 2016, 9409363 (2016).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"1337_CR77","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/nu14061220","volume":"14","author":"A Pignolo","year":"2022","unstructured":"Pignolo, A. et al. Vitamin D and Parkinson\u2019s disease. Nutrients 14, 1220 (2022).","journal-title":"Nutrients"},{"key":"1337_CR78","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/jnr.23115","volume":"90","author":"KVQ Luong","year":"2012","unstructured":"Luong, K. V. Q. & Nguyen, L. T. H. Vitamin D and Parkinson\u2019s disease. J. Neurosci. Res. 90, 2227\u20132236 (2012).","journal-title":"J. Neurosci. Res."},{"key":"1337_CR79","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1093\/brain\/aww175","volume":"139","author":"RS Weil","year":"2016","unstructured":"Weil, R. S. et al. Visual dysfunction in Parkinson\u2019s disease. Brain 139, 2827\u20132843 (2016).","journal-title":"Brain"},{"key":"1337_CR80","doi-asserted-by":"crossref","unstructured":"Pareek, A. et al. Retinoic acid in Parkinson\u2019s disease: Molecular insights, therapeutic advances, and future prospects. Life Sci. 355, 123010 (2024).","DOI":"10.1016\/j.lfs.2024.123010"},{"key":"1337_CR81","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00702-018-1952-7","volume":"126","author":"JPM Finberg","year":"2019","unstructured":"Finberg, J. P. M. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson\u2019s disease. J. Neural Transm. 126, 433\u2013448 (2019).","journal-title":"J. Neural Transm."},{"key":"1337_CR82","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1113\/jphysiol.2010.203257","volume":"589","author":"Y Yanovsky","year":"2011","unstructured":"Yanovsky, Y. et al. l-Dopa activates histaminergic neurons. J. Physiol. 589, 1349\u20131366 (2011).","journal-title":"J. Physiol."},{"key":"1337_CR83","doi-asserted-by":"publisher","first-page":"e70008","DOI":"10.1111\/jpi.70008","volume":"76","author":"F Galvani","year":"2024","unstructured":"Galvani, F., Cammarota, M., Vacondio, F., Rivara, S. & Boscia, F. Protective activity of melatonin combinations and melatonin-based hybrid molecules in neurodegenerative diseases. J. Pineal Res. 76, e70008 (2024).","journal-title":"J. Pineal Res."},{"key":"1337_CR84","doi-asserted-by":"publisher","first-page":"1265789","DOI":"10.3389\/fneur.2023.1265789","volume":"14","author":"S Iftikhar","year":"2023","unstructured":"Iftikhar, S. & Sameer, H. M. & Zainab. Significant potential of melatonin therapy in Parkinson\u2019s disease-a meta-analysis of randomized controlled trials. Front. Neurol. 14, 1265789 (2023).","journal-title":"Front. Neurol."},{"key":"1337_CR85","doi-asserted-by":"publisher","first-page":"9915","DOI":"10.1021\/ja404004v","volume":"135","author":"SK Bae","year":"2013","unstructured":"Bae, S. K. et al. A ratiometric two-photon fluorescent probe reveals reduction in mitochondrial H2S production in Parkinson\u2019s disease gene knockout astrocytes. J. Am. Chem. Soc. 135, 9915\u20139923 (2013).","journal-title":"J. Am. Chem. Soc."},{"key":"1337_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3892\/ijmm.2024.5461","volume":"55","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Adrenic acid: A promising biomarker and therapeutic target. Int. J. Mol. Med. 55, 20 (2024).","journal-title":"Int. J. Mol. Med."},{"key":"1337_CR87","doi-asserted-by":"publisher","first-page":"IJTR","DOI":"10.4137\/IJTR.S2469","volume":"2","author":"RS Grant","year":"2009","unstructured":"Grant, R. S., Coggan, S. E. & Smythe, G. A. The physiological action of picolinic acid in the human brain. Int. J. tryptophan Res. 2, IJTR\u2013S2469 (2009).","journal-title":"Int. J. tryptophan Res."},{"key":"1337_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep11864","volume":"5","author":"R Weng","year":"2015","unstructured":"Weng, R. et al. Metabolomics approach reveals integrated metabolic network associated with serotonin deficiency. Sci. Rep. 5, 1\u201313 (2015).","journal-title":"Sci. Rep."},{"key":"1337_CR89","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry 87, 295\u2013301 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1337_CR90","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.parkreldis.2019.01.012","volume":"63","author":"D Mac\u00edas-Garc\u00eda","year":"2019","unstructured":"Mac\u00edas-Garc\u00eda, D. et al. Increased bilirubin levels in Parkinson\u2019s disease. Park. Relat. Disord. 63, 213\u2013216 (2019).","journal-title":"Park. Relat. Disord."},{"key":"1337_CR91","first-page":"145","volume":"9","author":"EK Tur","year":"2022","unstructured":"Tur, E. K. & Buse, \u00c7A. Assessment of Bilirubin Levels in Parkinson\u2019s Disease. Bosphorus Med. J. 9, 145 (2022).","journal-title":"Bosphorus Med. J."},{"key":"1337_CR92","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ana.25048","volume":"82","author":"L Straniero","year":"2017","unstructured":"Straniero, L. et al. DNAJC12 and dopa-responsive nonprogressive parkinsonism. Ann. Neurol. 82, 640\u2013646 (2017).","journal-title":"Ann. Neurol."},{"key":"1337_CR93","doi-asserted-by":"publisher","first-page":"16176","DOI":"10.3390\/ijms232416176","volume":"23","author":"MR Ceccarini","year":"2022","unstructured":"Ceccarini, M. R. et al. The polyunsaturated fatty acid EPA, but not DHA, enhances neurotrophic factor expression through epigenetic mechanisms and protects against parkinsonian neuronal cell death. Int. J. Mol. Sci. 23, 16176 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1337_CR94","doi-asserted-by":"crossref","unstructured":"Madiraju, S. R. M., Possik, E., Al-Mulla, F., Nolan, C. J. & Prentki, M. Glycerol and glycerol-3-phosphate: Multifaceted metabolites in metabolism, cancer, and other diseases. Endocr. Rev. 47, 93\u2013120 (2026).","DOI":"10.1210\/endrev\/bnaf033"},{"key":"1337_CR95","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1440-1681.2011.05599.x","volume":"39","author":"C Nicholls","year":"2012","unstructured":"Nicholls, C., Li, H. & Liu, J.-P. GAPDH: A common enzyme with uncommon functions. Clin. Exp. Pharmacol. Physiol. 39, 674\u2013679 (2012).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1337_CR96","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.neuroscience.2011.06.050","volume":"192","author":"J Huang","year":"2011","unstructured":"Huang, J. et al. Glyceraldehyde-3-phosphate dehydrogenase: activity inhibition and protein overexpression in rotenone models for Parkinson\u2019s disease. Neuroscience 192, 598\u2013608 (2011).","journal-title":"Neuroscience"},{"key":"1337_CR97","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1007\/s12035-024-04090-y","volume":"61","author":"Y-L Ren","year":"2024","unstructured":"Ren, Y.-L. et al. Loss of CHCHD2 stability coordinates with C1QBP\/CHCHD2\/CHCHD10 complex impairment to mediate PD-linked mitochondrial dysfunction. Mol. Neurobiol. 61, 7968\u20137988 (2024).","journal-title":"Mol. Neurobiol."},{"key":"1337_CR98","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41531-024-00732-z","volume":"10","author":"X Luo","year":"2024","unstructured":"Luo, X., Liu, Y., Balck, A., Klein, C. & Fleming, R. M. T. Identification of metabolites reproducibly associated with Parkinson\u2019s Disease via meta-analysis and computational modelling. npj Park. Dis. 10, 126 (2024).","journal-title":"npj Park. Dis."},{"key":"1337_CR99","doi-asserted-by":"publisher","first-page":"1594330","DOI":"10.3389\/fncom.2025.1594330","volume":"19","author":"X Luo","year":"2025","unstructured":"Luo, X., El Assal, D. C., Liu, Y., Ranjbar, S. & Fleming, R. M. T. Constraint-based modeling of bioenergetic differences between synaptic and non-synaptic components of dopaminergic neurons in Parkinson\u2019s disease. Front. Comput. Neurosci. 19, 1594330 (2025).","journal-title":"Front. Comput. Neurosci."},{"key":"1337_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-4-48","volume":"4","author":"T Cakir","year":"2007","unstructured":"Cakir, T., Alsan, S., Sayba\u015fili, H., Akin, A. & \u00dclgen, K. \u00d6 Reconstruction and flux analysis of coupling between metabolic pathways of astrocytes and neurons: application to cerebral hypoxia. Theor. Biol. Med. Model. 4, 48 (2007).","journal-title":"Theor. Biol. Med. Model."},{"key":"1337_CR101","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.fob.2014.05.006","volume":"4","author":"M Sertba\u015f","year":"2014","unstructured":"Sertba\u015f, M., \u00dclgen, K. & \u00c7akir, T. Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network. FEBS Open Bio 4, 542\u2013553 (2014).","journal-title":"FEBS Open Bio"},{"key":"1337_CR102","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1371\/journal.pgen.0030098","volume":"3","author":"TG Lesnick","year":"2007","unstructured":"Lesnick, T. G. et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 3, e98 (2007).","journal-title":"PLoS Genet"},{"key":"1337_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-005-0020-2","volume":"7","author":"LB Moran","year":"2006","unstructured":"Moran, L. B. et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson\u2019s disease. Neurogenetics 7, 1\u201311 (2006).","journal-title":"Neurogenetics"},{"key":"1337_CR104","doi-asserted-by":"publisher","first-page":"52ra73","DOI":"10.1126\/scitranslmed.3001059","volume":"2","author":"B Zheng","year":"2010","unstructured":"Zheng, B. et al. PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease. Sci. Transl. Med. 2, 52ra73\u201352ra73 (2010).","journal-title":"Sci. Transl. Med."},{"key":"1337_CR105","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00401-012-1027-z","volume":"124","author":"PF Durrenberger","year":"2012","unstructured":"Durrenberger, P. F. et al. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol. 124, 893\u2013903 (2012).","journal-title":"Acta Neuropathol."},{"key":"1337_CR106","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13115","volume":"19","author":"A Simchovitz","year":"2020","unstructured":"Simchovitz, A. et al. A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson\u2019s disease substantia nigra. Aging Cell 19, e13115 (2020).","journal-title":"Aging Cell"},{"key":"1337_CR107","doi-asserted-by":"publisher","first-page":"e0128651","DOI":"10.1371\/journal.pone.0128651","volume":"10","author":"AA Dijkstra","year":"2015","unstructured":"Dijkstra, A. A. et al. Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson\u2019s disease. PLoS One 10, e0128651 (2015).","journal-title":"PLoS One"},{"key":"1337_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"1337_CR109","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"1337_CR110","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Res"},{"key":"1337_CR111","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41596-018-0098-2","volume":"14","author":"L Heirendt","year":"2019","unstructured":"Heirendt, L. et al. Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v. 3.0. Nat. Protoc. 14, 639\u2013702 (2019).","journal-title":"Nat. Protoc."},{"key":"1337_CR112","doi-asserted-by":"publisher","first-page":"W83","DOI":"10.1093\/nar\/gkw199","volume":"44","author":"J Reimand","year":"2016","unstructured":"Reimand, J. et al. g: Profiler\u2014a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 44, W83\u2013W89 (2016).","journal-title":"Nucleic Acids Res"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01337-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01337-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01337-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:02:33Z","timestamp":1782086553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01337-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01337-4","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}